Serious interaction between mibefradil and tacrolimus

Transplantation

Volumn 66, Issue 8, 1998, Pages 1113-1115

  Krähenbühl, Stephan ^a   Menafoglio, Andrea ^b   Giostra, Emile ^c   Gallino, Augusto ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

^c UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; MIBEFRADIL; NIFEDIPINE; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; CONFUSION; DRUG BLOOD LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER TRANSPLANTATION; PRIORITY JOURNAL;

BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MIBEFRADIL; MIDDLE AGED; TACROLIMUS; TETRAHYDRONAPHTHALENES;

EID: 0344193613     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199810270-00026     Document Type: Article

References (13)

1. Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996; 8: 710.
2. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423.
3. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporin for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
4. Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54: 925.
5. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281.
6. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404.
7. Oparil S, Bernink P, Bursztyn M, Carney S, Kobrin I. Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension. Am J Cardiol 1997; 80: 12C.
8. Massie BM, Lacourcière Y, Viskoper R, Woittiez A, Kobrin I. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists. Am J Cardiol 1997; 80: 27C.
9. Christians U, Schmidt G, Bader A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996; 41: 187.
10. Cakaloglu Y, Tredger JM, Devlin J, Williams R. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK506 and cyclosporine in liver transplant recipients. Hepatology 1994; 20: 309.
11. Lemoine A, Azoulay D, Dennison A, et al. FK506 renal toxicity and lack of detectable cytochrome P-4503A in the liver graft of a patient undergoing liver transplantation. Hepatology 1994; 20: 1472.
12. Jensen C, Jordan M, Shapiro R, et al. Interaction between tacrolimus and erythromycin. Lancet 1994; 344: 825.
13. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41.